Cystatin C: a better marker to detect coronary artery sclerosis. 2009

Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, Kawasaki-City, Kanagawa, 216-8511 Japan. sekimal@marianna-u.ac.jp

BACKGROUND Nowadays, early detection and treatment can often keep chronic kidney disease patients from getting worse and prevent the occurrence of cardiovascular disease. Cystatin C (Cys-C) is a new marker for renal dysfunction. This study investigated whether Cys-C played an important role for screening coronary artery disease. METHODS The consecutive 88 outpatients (51 males and 37 females), who were suspected of having effort angina pectoris or asymptomatic ischemic heart disease, were enrolled. Serum Cys-C, which was obtained within 3 months before coronary angiography, was assessed with the presence or absence of coronary arteriosclerosis, the number of culprit arteries, and blood biochemical parameters. RESULTS Mean serum Cys-C was 0.82+/-0.29 mg/l. Significant differences in the estimated creatinine clearance (p=0.036), hemoglobin A1c (p=0.01), left ventricular ejection fraction (p=0.01), creatinine (p=0.007), Cys-C (p=0.006), and high-density lipoprotein (HDL) cholesterol (p=0.001) were observed between the patients with or without coronary arteriosclerosis. Serum Cys-C was significantly greater in the multi-vessel disease (MVD) group than the 0 vessel disease (0VD) group (p<0.001). HDL cholesterol was significantly lower in the MVD group than the 0VD and single-vessel disease groups (p=0.002 and p=0.005, respectively). CONCLUSIONS The results of this study suggest Cys-C might be one of the risk factors for coronary arteriosclerosis in the patients with suspected ischemic heart disease without any history of coronary artery disease. Cys-C was a useful marker to detect coronary artery disease and the level of Cys-C could reflect the severity of coronary arteriosclerosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
March 2010, Pediatric nephrology (Berlin, Germany),
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
September 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
January 2015, PloS one,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
April 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
November 2003, Journal of the American Geriatrics Society,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
October 2020, Cureus,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
September 2013, Atherosclerosis,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
January 2008, Medicina clinica,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
February 2017, Bulletin of experimental biology and medicine,
Hiromitsu Sekizuka, and Yoshihiro J Akashi, and Kensuke Kawasaki, and Masahiro Yamauchi, and Haruki Musha
January 2001, Scandinavian journal of clinical and laboratory investigation,
Copied contents to your clipboard!